Cargando…
The Use of PDX1 DNA Methylation to Distinguish Two Subtypes of Pancreatic Neuroendocrine Neoplasms with Different Prognoses
Autores principales: | Ungefroren, Hendrik, Konukiewitz, Björn, Wellner, Ulrich F., Schrader, Jörg, Keck, Tobias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818131/ https://www.ncbi.nlm.nih.gov/pubmed/36612156 http://dx.doi.org/10.3390/cancers15010160 |
Ejemplares similares
-
PDX1 DNA Methylation Distinguishes Two Subtypes of Pancreatic Neuroendocrine Neoplasms with a Different Prognosis
por: Boons, Gitta, et al.
Publicado: (2020) -
Elucidation of the Role of SMAD4 in Epithelial–Mesenchymal Plasticity: Does It Help to Better Understand the Consequences of DPC4 Inactivation in the Malignant Progression of Pancreatic Ductal Adenocarcinoma?
por: Ungefroren, Hendrik, et al.
Publicado: (2023) -
Differential Effects of Somatostatin, Octreotide, and Lanreotide on Neuroendocrine Differentiation and Proliferation in Established and Primary NET Cell Lines: Possible Crosstalk with TGF-β Signaling
por: Ungefroren, Hendrik, et al.
Publicado: (2022) -
A Comprehensive Molecular Characterization of the Pancreatic Neuroendocrine Tumor Cell Lines BON-1 and QGP-1
por: Luley, Kim B., et al.
Publicado: (2020) -
TAp73 Inhibits EMT and Cell Migration in Pancreatic Cancer Cells through Promoting SMAD4 Expression and SMAD4-Dependent Inhibition of ERK Activation
por: Ungefroren, Hendrik, et al.
Publicado: (2023)